Romaco delivers first Siebler StripTabs to Indian contract manufacturer

Published: 22-Jan-2010
Packaging Drug Delivery Pharmaceutical

Romaco has developed its first Siebler StripTabs line for Ankur Drugs and Pharma, based in Baddi and Daman, India.

Romaco has developed its first Siebler StripTabs line for Ankur Drugs and Pharma based in Baddi and Daman, India. It will be used for the production and packaging of pharmaceutical orally dissolving strips for pain and hormone therapies, as well as for treating erectile disfunction. Taken orally, the wafer-thin StripTabs dissolve on the tongue in seconds.

This type of medication, based on a starch and polymer solution, is currently being considered as a carrier for more than 600 different APIs.

"This innovative pharmaceutical dosage form has the potential dramatically to change and expand the landscape of traditional dosage forms," says Purnandu Jain, chief executive of Ankur Drugs and Pharma.

The Indian company is currently using more than 50 blister and strip packaging lines, cartoners, tube fillers, as well as aseptic powder filling lines made by packaging specialist Romaco of Karlsruhe, Germany. It currently produces and packages more than 400 different drugs for the Indian, Asian and African pharmaceutical markets.

Customised manufacturing and packaging processes are needed to handle the thumb-sized strip dosage forms, which are only 60-100μm thick. First, the active pharmaceutical ingredient suspension is prepared using a homogenising process on a vacuum-processing unit made by Romaco FrymaKoruma. Directly blending in the APIs, right at the beginning of the process, results in high dosing accuracy, the company says.

The liquid is then applied with a thickness tolerance of 1μm to a high-precision substrate film. After being conveyed through several drying units, the coated strips are wound into rolls with widths of up to 240mm, which are transferred to a Siebler HM 2/500 heat sealing machine for further processing.

After unrolling, the coated substrate strips are conveyed through the unit's cutting station and the film tablets cut to the required dimensions of 20 x 30mm, leaving the carrier material intact.

In the next step, the cut strips are pulled over a sharp-edged dispensing tongue where they become separated from the substrate film and are conveyed as individual units to the sealing area.

A shuttle system carries the individual film tablets onto the primary packaging film with a sealing width of up to 500mm.

The StripTabs then come to the HM 2/500's ten-line sealing process, which has a maximum packaging speed of 1,500 strips/min. Sealed in light- and moisture-proof soft aluminum foil pouches, the StripTabs have a shelf life of up to three years.
See more

You may also like

Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

Read more
The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    From proof-of-concept to commercial reality: a turning point for microneedle drug delivery A 50% reduction in microarray patch production costs demonstrates that scalable, automated MAP manufacturing is now commercially viable — clearing a critical barrier to mainstream pharmaceutical adoption
  2. Why weight sorting should move earlier in OSD development Phillip Ruda explains how earlier weight intelligence can improve process understanding, reduce risk and accelerate learning cycles
  3. Lyocontract invests €50m in new freeze-drying facility with Syntegon vial line German CDMO Lyocontract has begun construction of a €50m expansion in Ilsenburg, partnering with Syntegon to install a complete vial filling and lyophilisation line for sterile freeze-dried pharmaceuticals
  4. Tablet-in-capsule technology: a versatile platform for complex oral solid dose development Tablet-in-capsule technology is redefining oral solid dosage development by enabling modular formulation design, differentiated release profiles and efficient fixed-dose combination strategies within a scalable, manufacturing-friendly platform

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates
Design & Build

Entries closed: what’s next for the Cleanroom Technology Awards?

With entries now closed, attention turns to the next phase of the awards programme
Manufacturing

Schütz to build automated IBC production facility at BASF's Ludwigshafen headquarters

Packaging specialist Schütz has signed an agreement with BASF to construct a highly automated intermediate bulk container manufacturing and storage facility directly adjacent to the chemical giant's main plant in Ludwigshafen, enabling round-the-clock just-in-time delivery
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities

The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258

The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
Subscribe now